ZIMVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.82 USD | +2.20% |
|
+2.53% | -10.87% |
| Apr. 01 | H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc.. | CI |
| Mar. 18 | ZimVie Inc.(NasdaqGS:ZIMV) added to S&P Healthcare Equipment Select Industry Index | CI |
Financials (USD)
| Sales 2024 * | 456M | Sales 2025 * | 461M | Capitalization | 431M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.94 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.93 x |
| P/E ratio 2024 * |
-4.32
x | P/E ratio 2025 * |
-5.33
x | Employees | 2,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on ZimVie Inc.
More recommendations
More press releases
| 1 day | +2.20% | ||
| 1 week | +2.53% | ||
| Current month | -4.06% | ||
| 1 month | -4.06% | ||
| 3 months | -15.67% | ||
| 6 months | +125.36% | ||
| Current year | -10.87% |
1 week
15.27
16.10
1 month
15.1619.52
Current year
15.1620.91
1 year
6.5220.91
3 years
5.0550.40
5 years
5.0550.40
10 years
5.0550.40
| Managers | Title | Age | Since |
|---|---|---|---|
Vafa Jamali
CEO | Chief Executive Officer | 54 | 21-01-31 |
| Director of Finance/CFO | 53 | 21-08-31 | |
Steve Rondeau
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David King
CHM | Chairman | 67 | 22-02-28 |
Richard Kuntz
BRD | Director/Board Member | 66 | 22-02-28 |
Sally Crawford
BRD | Director/Board Member | 70 | 22-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 8 M€ | +3.41% | - | |
| 0.02% | 18 M€ | +3.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 15.82 | +2.20% | 143,539 |
| 24-04-25 | 15.48 | -2.09% | 144,434 |
| 24-04-24 | 15.81 | -1.50% | 117,593 |
| 24-04-23 | 16.05 | +3.62% | 250,058 |
| 24-04-22 | 15.49 | +0.39% | 183,718 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
ZimVie Inc. is a global life sciences company in the dental market. The Company develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. The Company works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including dental implants, biomaterials, and digital workflow solutions. In the dental segment, its core services include designing, manufacturing and distributing dental implant systems. The key products in its dental implant systems portfolio include the T3 Implant, Tapered Screw-Vent Implant System, Trabecular Metal Dental Implant, BellaTek Encode Impression System, and Puros Allograft Particulate. The Company markets its products in about 70 countries in North America, Europe, Latin America and Asia.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Related indices
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
15.82
USD
Average target price
16
USD
Spread / Average Target
+1.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.87% | 431M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.07B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- ZIMV Stock
